Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference
July 06 2021 - 6:00AM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that
utilizes its human memory B cell discovery engine platform to
discover and develop first-in-class antibody therapeutics, today
announced that Purnanand Sarma, Ph.D., Immunome’s President and
CEO, will present at the Ladenburg Thalmann 2021 Healthcare
Conference on Tuesday, July 13, 2021, at 10:30 a.m. ET.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company's
website at www.immunome.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 30
days.
About Immunome
Immunome is a biopharmaceutical company that utilizes its
proprietary human memory B cell platform to discover and develop
first-in-class antibody therapeutics that are designed to change
the way diseases are treated. The company’s initial focus is on
developing therapeutics to treat oncology and infectious diseases,
including COVID-19. Immunome’s proprietary discovery engine
identifies novel therapeutic antibodies and their targets by
leveraging the highly educated components of the immune system,
memory B cells, from patients whose bodies have learned to fight
off their disease. For more information, please visit
www.immunome.com.
Forward-Looking Statements
This press release includes certain disclosures that contain
“forward-looking statements” intended to qualify for the “safe
harbor” from liability established by the Private Securities
Litigation Reform Act of 1995, as amended, including, without
limitation, express or implied statements regarding Immunome’s
beliefs and expectations regarding the advancement of its oncology
and COVID-19 therapeutic antibody programs, execution of its
clinical and strategic plans, anticipated upcoming milestones for
IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding
therapeutic potential and benefits thereof, and IND filings.
Forward-looking statements may be identified by the words
“anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,”
“project,” “may,” “will,” “could,” “should,” “seek,” “potential”
and similar expressions. Forward-looking statements are based on
Immunome’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, those risks and uncertainties associated with: the
impact of the COVID-19 pandemic on Immunome’s business, operations,
strategy, goals and anticipated milestones; Immunome’s ability to
execute on its strategy including with respect to the timing of its
R&D efforts, IND filings, initiation of clinical studies and
other anticipated milestones; the timing and effectiveness of any
antibody therapeutics which may be developed by Immunome;
Immunome’s ability to fund operations; and the additional risks and
uncertainties set forth more fully under the caption “Risk Factors”
in Immunome’s Annual Report on Form 10-K filed with the United
States Securities and Exchange Commission (SEC) on March 25, 2021,
and elsewhere in Immunome’s filings and reports with the SEC.
Forward-looking statements contained in this announcement are made
as of this date, and Immunome undertakes no duty to publicly update
or revise any forward looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210706005236/en/
Immunome Contact Purnanand Sarma, PhD Chief Executive
Officer Immunome, Inc. investors@immunome.com
Investor Contact Laurence Watts Managing Director
Gilmartin, LLC laurence@gilmartinir.com
Immunome Media Contact Megan McGrath or Nick Chang
MacDougall 781-235-3060 mmcgrath@macbiocom.com or
nchang@macbiocom.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Apr 2024 to May 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From May 2023 to May 2024